News and Events

NJ Bio’s, CEO, Dr. Naresh Jain will be presenting at two notable conferences in Asia at the start of 2026. Starting with BIOLOGICS 2026 in India, Dr. Jain will deliver a thought-provoking talk titled “Is ADC a Magic Bullet or a Work of Delicate Balance?” He will break...

NJ Bio, Inc. has been recognized by its long-standing client, Exelixis, for delivering outstanding service in 2025. This recognition highlights the company’s strong scientific and technical expertise, the innovative implementation of innovative solutions, and...

NJ Bio is proud to share the first published 2D NMR spectra of antibody-drug conjugates (ADCs), showcasing NMR’s ability to deliver deep insights into ADC higher-order structure (HOS) and the structural impacts on efficacy. The HOS can be a great tool for...

NJ Bio, Inc. is thrilled to be recognized as the Runner-Up in the Best CRO (Contract Research Organization) category at the 12th Annual World ADC Awards in San Diego. This distinction celebrates the company’s excellence, innovation, and impact in the ADC space. NJ Bio...

NJ Bio is proud to announce its participation in the upcoming TIDES Europe Conference, taking place in Basel, Switzerland, from November 11–13, 2025, alongside the Sapala team. Through the years, this event has become a premier global platform for innovation in...

NJ Bio, Inc. is excited to announce its participation in the BIO International Convention 2025, to be held from June 16-19, at the Boston Convention & Exhibition Center. It is one of the largest and most comprehensive events in the biotech industry, bringing...

NJ Bio, Inc., will be participating in the AACR Annual Meeting, taking place from April 25–30, 2025, at McCormick Place Convention Center, Chicago, Illinois. AACR, the largest conference in cancer research, brings together scientists, clinicians and professionals...

NJ Bio, Inc. is excited to announce its strategic partnership with Suven Pharmaceuticals, a leading CDMO based in Hyderabad, India. Suven, backed by Boston-based private equity firm Advent International, has acquired a 56% equity stake in NJ Bio through a $64.4...

NJ Bio, Inc., has been awarded the prestigious Best Contract Research Organization (CRO) title at the 11th Annual World ADC Awards in San Diego, marking the company's fourth consecutive win. This successive win underscores NJ Bio’s commitment and the continued trust...

NJ Bio, Inc., is excited to announce a new strategic collaboration with Charles River Laboratories (CRL) aimed at enhancing ADC manufacturing capabilities and accelerating the journey of ADC programs from the laboratory to the clinic. This partnership combines CRL’s...

NJ Bio, Inc. is thrilled to announce its participation in the BIO International Convention 2024, one of the largest and most comprehensive events in the biotech industry. The convention, scheduled from June 3-6, 2024, at the San Diego Convention Center, will host over 20,000 industry leaders from around the globe, offering a unique platform for networking, collaboration, and innovation. Attendees can look forward to a wide array of sessions and exhibits focused on the latest research and emerging technologies in the biotech sector.

NJ Bio, Inc., is thrilled to announce its participation in several prestigious conferences this year. Starting the year with a strong presence, NJ Bio will be participating in the renowned AACR Annual Meeting, a premier event in cancer research and medicine. Scheduled...

NJ Bio, Inc., is delighted to announce its recent honor as the recipient of the “Best Contract Research Organization” (CRO) Award at the 10th Annual World ADC Awards. The award serves as a testament to NJ Bio's unwavering commitment to delivering innovative solutions...

NJ Bio, Inc., took the global stage at the 14th Annual World ADC conference, shedding light on a prevalent challenge in the world of Antibody-Drug Conjugates (ADCs). The issue at hand: the replication of ideas (or as we term it the “copy-paste” approach) and a...

NJ Bio, Inc., had the privilege of hosting Senior Vice President, Head of Biologics & Biotherapeutics at Exelixis, Inc., Dr. Seema Kantak, at our headquarters in Princeton.

The World ADC Awards is a platform that acknowledges creativity, innovation, leadership and devotion in the field of antibody-drug conjugates. This year Hanson Wade is back with the 10th Annual ADC Awards, celebrating a decade of honoring the very best in the field....

NJ Bio is thrilled to share that the Honorable Ms. Kiran Mazumdar Shaw inaugurated the “Center for NMR Excellence” equipped with the state-of-the-art JEOL 800 MHz and Bruker 700MHz NMR spectrometers at our Princeton headquarters. Kiran Mazumdar Shaw, a renowned...

NJ Bio, Inc. is extremely grateful to Professor Vivek Gupta, Chairperson of the AAPS Discussion Group, and the NERDG committee for inviting our President & CEO, Dr. Naresh Jain, as a keynote speaker at the 25th Annual AAPS NERDG Conference. It was an honor to be...

NJ Bio, Inc. was pleased to welcome Dr. Yutaka Matsuda and his colleague Mr. Hiroki Imai (Business Development Manager) from Ajinomoto Bio-Pharma Services to our headquarters in Princeton. Dr. Yutaka Matsuda is a double Ph.D. and an expert in site-specific chemical...

NJ Bio, Inc., had the great honor to welcome their esteemed SAB member, Fellow of The American Institute for Medical and Biological Engineering (AIMBE) and renowned biotechnology consultant, Dr. Ravi Chari, to their headquarters in Princeton, New Jersey in January...

NJ Bio, Inc. enters into a global license and assignment agreement with Aarvik Therapeutics Inc., to develop next-generation ADCs using their novel class of payloads and Aarvik’s innovative therapeutic antibodies. In the recently finalized agreement, Aarvik...

On 29th November 2022, NJ Bio, Inc., had the distinct pleasure of welcoming a good friend and mentor, Dr. Thomas (Tom) Nittoli from Regeneron Pharmaceuticals, Inc. to share his views on advancing conjugated antibodies and proteins from discovery to development of...

On November 9th and 10th, 2022, NJ Bio, Inc. hosted two esteemed ADC researchers, Dr. Jagath Reddy Junutula, President, CEO, and Co-founder of Aarvik Therapeutics Inc. and Dr. Brian Mendelsohn, Executive Director, Antibody Drug Conjugates at Exelixis, Inc....

NJ Bio, Inc. was proud to be a program partner at 5th Annual TPD Summit held in Boston between October 25 – 28, 2022. Our distinguished research leader, David C. Fry, Ph.D. was an expert speaker at the event. Dr. Fry has expertise in NMR analysis of proteins,...

NJ Bio, Inc. was awarded the 9th Annual World ADC Award for Best Contract Research Provider category at the 13th Annual World ADC Conference 2022 held in San Diego. Through the years, the Annual World ADC Awards recognizes innovation, and leadership within the...

Over the years, NJ Bio, Inc. has stayed committed to the Antibody Drug Conjugates (ADCs) field by sponsoring several distinguished events in this space and has dedicated itself to educating the global community about this emerging area of innovation. We received yet...